Compare Ishares Msci Brazil ETF (EWZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Ishares Msci Brazil ETF trades at $43.54 (market cap $11.30B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: Ishares Msci Brazil ETF and State Street SPDR S&P Biotech ETF are close in size by market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| EWZ | XBI | |
|---|---|---|
Market Cap | $11.30B | $10.11B |
Volume | 44,036,597 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $43.00 | $169.55 |
52-Week Low | $28.79 | $104.99 |
Typical Hold Time | 50 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, is trading at $43.54, up 2.76% today, with strong bullish momentum from moving averages but overbought RSI signals. The ETF is positioned as a diversification play against U.S. tech concentration, benefiting from Brazil's commodity exposure and election-driven optimism. Recent unusual options activity and institutional buying reflect heightened investor interest ahead of October's presidential election.
The outlook hinges on Brazil's election outcome and commodity trends, offering asymmetric upside via call spreads. Risks include political volatility, U.S. tariff impacts, and competition from lower-fee Brazil ETFs like FLBR. Wall Street sentiment is cautiously optimistic, with the trade acting as a hedge against AI-driven U.S. market risks.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
